Description: Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates.
Home Page: www.cingulate.com
CING Technical Analysis
1901 West 47th Place
Kansas City,
KS
66205
United States
Phone:
913 942 2300
Officers
| Name | Title |
|---|---|
| Dr. Shane J. Schaffer Pharm.D., PharmD | CEO & Chairman |
| Mr. Louis G. Van Horn CPA, M.B.A. | Exec. VP & CFO |
| Dr. Laurie A. Myers M.B.A., Ph.D. | Exec. VP & COO |
| Mr. Craig S. Gilgallon Esq. | Exec. VP, Gen. Counsel & Board Sec. |
| Dr. Raul R. Silva M.D. | Exec. VP & Chief Science Officer |
| Thomas Dalton | Head of Investor & PR |
| Dr. Matthew N. Brams M.D. | Exec. VP & Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2354 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-12-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 16 |